Exelixis, inc. (EXEL)
CashFlow / Yearly
Jan'20Dec'18Dec'17Dec'16Jan'16Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities:
Net income

321,012

690,070

154,227

-70,222

-161,744

-261,297

-244,760

-147,645

75,697

-92,330

-139,557

Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation

8,348

4,915

1,187

1,002

1,406

2,391

3,147

5,513

6,822

10,543

12,595

Stock-based compensation

56,602

40,626

23,938

22,912

21,977

10,006

12,031

8,833

12,099

21,112

22,906

Non-cash lease expense

2,819

2,854

0

-

-

-

-

-

-

-

-

401(k) matching contributions made in common stock

-

-

-

1,036

-

-

-

-

-

-

-

Amortization and other right-of-use assets

-

-

-

0

-

-

-

-

-

-

-

Deferred taxes

-71,002

244,111

0

0

-

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

-

-13,901

0

0

-

-

-

-

-

Amortization of debt discounts and debt issuance costs

-

-

-

8,432

17,041

22,289

26,290

14,752

7,989

3,596

-

Restructuring charge for property and equipment

-

-

-

-

-

-

-

-

497

3,327

-

Interest paid in kind

-

-

-

8,008

3,817

0

0

-

-

-

-

Gain on other equity investments

-

-

-

2,494

112

838

0

0

2,254

8,197

2,052

Gain on sale of property and equipment

-

-

-

-

-

-

-

-

0

0

-

Changes in warrant fair value

-

-

-

-

548

-1,840

0

0

-

-

-

Loss on deconsolidation of Symphony Evolution, Inc.

-

-

-

-

-

-

-

-

-

-

9,826

Other, net

-88

-1,129

6,795

-562

-1,861

-4,161

-6,787

-4,039

-4,801

-3,234

-1,619

Changes in operating assets and liabilities:
Trade receivables, net

-43,716

85,471

43,299

38,680

-

-

-

-

-

-

-

Trade and other receivables

-

-

-

-3,362

540

941

1,190

-27,038

24,294

-5,968

8,505

Inventory

5,731

3,181

3,319

722

235

-509

2,890

0

0

-

-

Prepaid expenses and other assets

5,723

8,525

378

1,610

325

-1,526

-1,034

1,764

-10,553

66

7,338

Accrued compensation and benefits

-

-

-

16,705

279

-9,447

-

-

-

-

-

Accrued clinical trial liabilities

-

-

-

-3,940

-23,474

6,587

14,398

1,169

9,246

-

-

Rebates and fees due customers

-

-

-

3,866

-

-

-

-

-

-

-

Accrued collaboration liability

-

-

-

-

10,206

-

-

-

-

-

-

Accounts payable, accrued compensation and benefits, and other accrued liabilities

-

-

-

-

-

-

8,691

5,149

-14,801

-9,444

9,008

Accrued collaboration liabilities

-

-

-

-10,938

10,206

732

0

-

-

-

-

Deferred revenue

-9,301

271

13,745

256,759

-2,582

1,133

-14,871

-41,920

-244,528

-42,945

85,777

Other long-term assets

-

-

-

-1,077

-1,340

2,149

0

1,966

-405

1,807

-6,424

Accounts payable and other liabilities

44,124

17,143

26,305

164

-12

-2,932

-

-

-

-

-

Long-term portion of lease liabilities

-

-

-

0

-

-

-

-

-

-

-

Restructuring liability

-

-

-

-

-

-

-5,750

5,244

-303

14,281

-

Other current and long-term liabilities

-

-

-

1,224

-10,502

-5,295

-1,690

-1,588

-1,162

-8,320

-5,294

Net cash provided by operating activities

526,956

415,720

165,611

210,404

-141,051

-235,405

-198,773

-123,146

-159,233

-101,048

-14,591

Cash flows from investing activities:
Purchases of investments held by Symphony Evolution, Inc.

-

-

-

-

-

-

-

-

-

-

49

Proceeds on sale of investments held by Symphony Evolution, Inc.

-

-

-

-

-

-

-

-

-

-

4,497

Purchases of property, equipment and other

12,834

33,297

21,143

1,703

447

474

2,171

2,717

991

1,811

5,908

Proceeds from sale of property and equipment

0

308

164

97

1,346

392

143

1,943

1,526

165

-

Purchases of investments

1,182,682

557,832

319,090

369,187

143,992

119,528

189,975

533,475

237,213

167,317

161,166

Proceeds from maturities and sales of investments

608,269

292,971

376,864

-

-

-

-

-

-

-

-

Proceeds from maturities of investments

-

-

-

151,485

178,936

252,891

325,171

310,765

124,800

127,569

49,767

Proceeds from sale of investments

-

-

-

2,266

0

0

-

-

55,205

12,780

766

Purchase of restricted cash and investments

-

-

-

-

5,650

8,143

6,085

41,485

5,899

8,099

-

Proceeds from sale of business

-

-

-

-

-

-

-

0

3,010

9,000

2,200

Proceeds from maturities of restricted cash and investments

-

-

-

-

-19,789

-20,354

-17,268

-5,499

-8,099

-8,144

2,429

Proceeds from other equity investments

-

-

-

2,494

95

838

0

-

-

-

-

Net cash provided by (used in) investing activities

-587,247

-297,850

36,795

-214,548

50,077

146,330

144,351

-259,470

-51,463

-19,569

-112,322

Cash flows from financing activities:
Proceeds from issuance of common stock under equity incentive plans

22,499

17,278

22,423

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net

-

-

-

-

145,649

75,643

0

203,479

179,375

0

-

Proceeds from exercise of stock options

-

-

-

25,327

10,911

120

72

929

12,436

2,684

-

Proceeds from employee stock purchase plan

-

-

-

2,187

568

1,438

1,429

1,217

1,734

3,132

3,826

Taxes paid related to net share settlement of equity awards

9,904

7,574

6,563

4,108

534

-

-

-

-

-

-

Principal payments on financing lease obligation

-

-

-

0

-

-

-

-

-

-

-

Principal repayments of debt

0

0

185,788

575

4,381

-11,709

-13,170

-4,870

-8,621

-39,563

-43,065

Other, net

-42

-13

0

-

-

-

-

-

-

-

-

Proceeds from debt issuance, net

-

-

-

-

-

-

-

277,673

2,589

165,008

-

Proceeds from exercise of stock options and warrants

-

-

-

-

-

-

-

-

-

-

273

Proceeds from notes payable and bank obligations

-

-

-

-

-

-

-

-

-

-

5,002

Redemption of convertible notes

-

-

-

-

-

0

-

-

-

-

-

Payments on conversion of convertible notes

-

-

-

7,135

0

0

-

-

-

-

-

Repayments, net from deconsolidation of Symphony Evolution, Inc.

-

-

-

-

-

-

-

-

-

-

-25

Net cash provided by financing activities

12,553

9,691

-169,928

15,696

152,213

65,492

-11,669

478,428

187,513

131,261

-33,989

Net increase in cash, cash equivalents and restricted cash

-47,738

127,561

32,478

11,552

61,239

-23,583

-66,091

95,812

-23,183

10,644

-160,902

Supplemental cash flow disclosure:
Cash paid for interest

0

0

20,460

21,044

19,822

19,109

19,160

6,982

6,835

11,059

10,532

Cash paid for taxes

7,873

10,677

538

190

192

60

0

1,118

0

0

-

Non-cash activities:
Right-of-use assets obtained in exchange for lease obligations

29,562

17,180

-

0

-

-

-

-

-

-

-

Property and equipment deemed to have been acquired in build-to-suit lease

0

0

14,530

0

-

-

-

-

-

-

-

Unpaid liabilities incurred for purchases of property and equipment

26

802

524

0

-

-

-

-

-

-

-

Issuance of warrants in connection with amendment to convertible notes

-

-

-

-

-

2,762

0

0

-

-

-

Construction in progress deemed to have been acquired under build-to-suit lease

-

-

-

-

0

-

-

-

-

-

-

Issuance of common stock in settlement of convertible notes

-

-

-

286,925

0

0

-

-

36,895

0

-